|Articles|December 14, 2022
Understanding the true cost of transparency reporting
Author(s)PwC
When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, new systems were quickly — and possibly haphazardly — put in place to handle snowballing transparency reporting requirements. Now the cracks are beginning to show, and PLS companies are realizing the true cost of transparency reporting.
Trending on PharmExec
1
FDA’s Advisory Panel Votes in Favor of Updating Covid-19 Vaccine Shots to Target XFG Variant
2
CVS Restores Coverage of Lilly’s Zepbound, Adds Oral Obesity Drug Foundayo
3
WHO Prioritizes Three Experimental Treatments for Bundibugyo Ebola Strain
4
FDA's Timeline for DTC Prescription Drug Ad Oversight
5